PRINCETON, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the âCompanyâ or âY-mAbsâ) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025.
Related Questions
Were there any notable collaborations, licensing deals, or partnership announcements that could impact future revenue streams?
What were YâmAbs' revenue and earnings figures for Q2 2025, and how do they compare to analyst expectations?
Did the company disclose any changes in its cost structure, SG&A expenses, or R&D spending that could influence profitability trends?
Did the company provide any updated guidance or outlook for Q3 2025 or the fullâyear 2025?
Are there any upcoming catalysts (e.g., FDA meetings, conference presentations) that could drive the stock price in the near term?
How does the reported cash balance and burn rate affect the company's runway and need for additional financing?
How does YâmAbs' Q2 performance compare to its main competitors in the radioimmunotherapy and antibodyâbased oncology space?
How might the sentiment score of 30 (presumably neutral) influence investor sentiment and trading volume for YMAB?
What progress was reported on the company's radioimmunotherapy pipeline, and are there any upcoming clinical trial readouts that could move the market?
What is the market's perception of the recent corporate developments (e.g., leadership changes, regulatory filings), and could they create shortâterm volatility?